Three poster presentations from Perspective Therapeutics’ scientists and collaborators explore combinations of immunotherapy and targeted alpha-particle therapy in a malignant melanoma model, ²⁰³Pb manufacturing, and In Vivo Distribution of Recoiled ²¹³Bi from [²²⁵Ac]Ac-DOTATATE

RICHLAND, WASHINGTON & CORALVILLE, Iowa, May 24, 2023 — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced it will be presenting three posters at the 2023 International Symposium on Radiopharmaceutical Sciences (iSRS) Annual Meeting being held in Hawaii from May 22-26, 2023.

“We are thrilled to present our latest research on targeted alpha therapies at the Society of Radiopharmaceutical Sciences annual meeting. Our scientists and collaborators have made significant progress in this field, and we are excited to share our findings with the wider scientific community. We believe that targeted alpha therapies have the potential to revolutionize cancer treatment, and we are committed to advancing this promising new approach.” said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer.

Michael Schultz, Perspective Therapeutics’ Chief Science Officer added, “I would like to thank our fabulous team of scientists and our collaborators for their relentless dedication to developing the best possible applications for our technology platform. This enables the best possible isotopes to be utilized to keep moving us toward the goal of improved cancer therapies. We are looking forward to discussing our findings with the global radiopharmaceutical science community at iSRS.”

Poster Presentation Summaries

Poster presentation #1: “Low-dose targeted alpha therapy induces strong anti-tumor effectiveness in combination with immune checkpoint inhibitors”

This poster shares the ongoing work by Perspective Therapeutics’ scientists and collaborators at the University of Wisconsin exploring the potential of targeted alpha therapies (TAT) in combination with established immune checkpoint inhibitor (ICI) therapies in preclinical melanoma models. The presented results confirm and extend the previously published preclinical work by the team, revealing long term curative responses from the combination of immunotherapies and TAT. In conclusion:

• When combined with dual ICIs, low doses of [²¹²Pb]VMT01 was more efficacious and resulted in complete tumor remission when compared with mid- and high-administered radioactivity doses. The immunostimulatory effects of TAT may not be linear to radiation dose. Therefore, the ideal dose of TAT that induces strongest anti-tumor efficacy with ICIs in melanoma needs to be further elucidated.

The poster will be presented during Poster Session 2A: Radionuclide Therapy on Wednesday May 24, 5:30PM – 6:15 PM HST in Kalākaua Ballroom A, by Samuel Rodman PhD, Research Scientist, Perspective Therapeutics.

Poster presentation #2: “Optimizing ²⁰³Pb cyclotron production and availability: The ideal SPECT imaging theranostic partner for ²¹²Pb targeted alpha therapy“

This poster discusses the Company’s continued work with its multi-institutional collaborators in order to improve the production methods for the SPECT isotope Pb-203 as part of its matched isotope theranostic pairing with Pb-212 targeted alpha therapy. The goal of this work is to ensure the availability of isotope supplies with high purity for ongoing imaging studies and for the Company’s pipeline of emerging products. In conclusion:

• Nuclear medicine centers with a 24 MeV cyclotron can produce and purify large ²⁰³Pb activities sufficient for clinical applications. This represents an attractive route to produce ²⁰³Pb for theranostic use as a SPECT radionuclide alongside ²¹²Pb targeted alpha therapy. The [²⁰³Pb]Pb(OAc)₂ product can be produced with high radiochemical purity – and radiolabeling experiments demonstrate strong potential for preclinical and clinical ²⁰³Pb radiopharmaceutical applications.

The poster will be presented during Poster Session 2A: Targetry on Wednesday May 24, 5:30PM – 6:15 PM HST in Kalākaua Ballroom A as presented by Bryce Nelson, University of Alberta.

Poster presentation #3: “Analysis of Radiochemical Stability and In Vivo Distribution of Recoiled ²¹³Bi from [²²⁵Ac]Ac-DOTATATE in Preclinical Model”

Targeted alpha-particle radiotherapies (TATs) have been evolving as promising treatments in management of cancers. Within this context, due to four alpha-particle emissions along the decay chain, ²²⁵Ac-based TATs have demonstrated superior tumor-killing efficacy compared with beta-particle emitters. However, the complex decay and recoil of daughters following the alpha-particle emission results in ambiguity in understanding the toxicity of these radiopharmaceuticals. In this study, we aimed to assess the ingrowth and radiochemical stability of ²¹³Bi and potential in vivo redistribution following the injection of [²²⁵Ac]Ac-DOTATATE in preclinical model. In conclusion:

• Although ²¹³Bi can be labeled initially, decoupling of ingrown free ²¹³Bi was inevitable with the decay of [²²⁵Ac]Ac-DOTATATE and significantly different biodistributions between the labeled ²²⁵Ac product and free ²¹³Bi are observed. Therefore, it is hypothesized that the radiochemical stability and biodistribution of recoiled daughters need to be characterized to better understand the potential toxicity resulted from injection of ²²⁵Ac -based TATs.

The poster will be presented during Poster Session 3: Radionuclide Therapy on Friday May 26, 2:45 PM – 3:30 PM HST in Kalākaua Ballroom A by Dijie Liu PhD DVM, Principal Research Scientist.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope Lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary Lead-212 generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com .

Safe Harbor Statement

Statements in this news release about Perspective Therapeutics’ future expectations, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing Perspective Therapeutics, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether additional studies are released that support the conclusions of the studies discussed in this news release, whether ongoing patient results are favorable and in line with the conclusions of clinical studies and initial patient results, physician acceptance, training and use of our products, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, changes in laws and regulations applicable to our products, and other risks detailed from time to time in Perspective Therapeutics, Inc. reports filed with the U.S. Securities Exchange Commission. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

LifeSci Advisors

Chuck Padala

E: chuck@lifesciadvisors.com

• Additional CDMO capabilities added to increase availability of clinical trial product in the US
• Phase I/IIa studies are initiating in the first half of 2023 for VMT-α-NET for neuroendocrine tumors and VMT-01 for melanoma

RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 — Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, reports first quarter financial results for the period ended March 31, 2023.

“Perspective Therapeutics is at an exciting juncture of our journey as we advance our clinical alpha-particle radiopharmaceutical pipeline. Simultaneously, we look to further support revenue expansion of our commercial brachytherapy program,” said Thijs Spoor, Perspective Therapeutics’ CEO. “In 2023, we expect to report provisional results from ongoing compassionate use of VMT-α-NET for neuroendocrine tumors. We also continue to move forward with our Phase I/IIa Dose Escalation Studies for VMT-α-NET for neuroendocrine tumors and VMT-01 for metastatic melanoma. In turn, we look forward to providing further program and pipeline updates to the market and we also expect incremental data to come out during major medical meetings over 2023.

“The first quarter of 2023 was an exciting one for the Company as we effected our merger, renamed the Company and initiated integration activities. Drafting off the excitement around the merger, we have also been able to attract some extraordinary talent and have added several key hires to the executive team in brachytherapy commercial leadership as well as an industry veteran in the radioactive materials supply chain.” Mr. Spoor concluded, “I’d like to give my express thanks to the entire Perspective Therapeutics team for leaning in during such a dynamic time for the Company while maintaining a focus on providing and developing treatments for cancer patients with an unshakeable focus on safety and quality.”

First Quarter 2023 Financial Summary

Revenue – Revenue for the three months ended March 31, 2023 was $2.1 million, as compared to $2.9 million in the same period in 2022, a decline of 29%. The year over year decline in revenue was primarily a result of the loss of a large customer partially offset by grant revenue from Viewpoint.

Gross Profit – Gross profit was $487,000 for the three months ended March 31, 2023 as compared to $1.4 million for the same period in 2022, a decline of 66%. The year over year decline was primarily a result of the decrease in sales due to the loss of a large customer along with higher production costs which were partially offset by grant revenue.

Research and development (R&D) expenses – R&D for the three months ended March 31, 2023 increased by $3.3 million compared to the three months ended March 31, 2022. The increase was due to $2.9 million related to the development of the Company’s alpha therapy drug products gained through the merger with Viewpoint along with increases in the Company’s legacy research and development expenses related to payroll costs, share based compensation, and brachytherapy trial protocol expense.

Net loss – For the first quarter of 2023, the Company reported a net loss of $371,000, compared to a net loss of $1.3 million in the same period in 2022. The lower net loss for the quarter ended March 31, 2023 was due to a deferred income tax benefit related to the acquisition of Viewpoint.

Cash and cash equivalents – As of March 31, 2023 cash and cash equivalents was $36.5 million as compared to cash, cash equivalents and short-term investments of $43.8 million as of December 31, 2022.

Investor Relations Contact:
LifeSci Advisors
Chuck Padala
E: chuck@lifesciadvisors.com

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT-01) and neuroendocrine tumor (VMT-α-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement
Statements in this news release about Perspective Therapeutics, Inc.’s (“Perspective”) and its wholly-owned operating subsidiaries Viewpoint Molecular Targeting, Inc.’s (“Viewpoint”) and Isoray Medical, Inc.’s (“Isoray,” and together with Viewpoint and Perspective, the “Company”) future expectations, including: the anticipated synergies and benefits of the merger between Perspective and Viewpoint; the anticipated pipeline of the Company’s programs and products; whether Phase I/IIa studies are initiated before June 30, 2023; whether provisional results for compassionate use of VMT-α-NET for neuroendocrine tumors are released; expectations about the Company’s addressable markets; the functionality and capabilities of the Company’s therapies including its targeted alpha-particle radiotherapy; the potential size of the commercial market for the Company’s treatment programs; the Company’s expectations, beliefs, intentions, and strategies regarding the future; and all other statements in this news release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing the Company of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as whether and to what extent the anticipated benefits of the merger are realized; the ability to raise ongoing capital to fund added costs of research and development related to the Company’s business; the ability of the Company to manage growth and successfully integrate its businesses; whether the Company can maintain its key employees; the risk that the merger disrupts current plans and operations; the outcome of any legal proceedings that may be instituted against the Company following consummation of the merger; whether the results of studies of targeted alpha-particle radiotherapy or using Cesium-131 in conjunction with immunotherapy combinations are conducted on the anticipated timelines or are successful; whether the Company’s anticipated product pipeline is achieved; whether additional studies are released that reinforce the results of the studies discussed in this presentation; whether the anticipated benefits of the Company’s therapies are realized; training and use of the Company’s products; market acceptance and recognition of the Company’s products; the Company’s ability to enforce its intellectual property rights; whether ongoing patient results are favorable and in line with the conclusions of clinical studies and initial patient results; successful completion of future research and development activities; whether we, our distributors, and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell, and use our products in their various forms; the procedures and regulatory requirements mandated by the FDA for animal trials, human trials, clinical studies, Phase I and II approvals and 510(k) approval and reimbursement codes; changes in applicable laws and regulations; and other risks detailed from time to time in the Company’s reports filed with the SEC.

Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. For more information regarding risks and uncertainties that could affect the Company’s results of operations or financial condition, please review our Form 10-KT filed on May 1, 2023 with the SEC.

• Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the Committee
• Michael McCormick announced his resignation and amicable departure from the Board of Directors

RICHLAND, WA & CORALVILLE, IA, May 15, 2023 — Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy powering expanding treatment options for multiple cancers, announced the following changes to the Board of Directors: the appointment of Heidi Henson to the Board of Directors and named Audit Committee Chair; taking over from Rob Williamson, III, who will continue to serve as a member of the Committee. Additionally, Michael McCormick announced his resignation and amicable departure from the Board of Directors

“We are living in exciting times as science, technology and medicine converge – creating new treatment paradigms and therapies for unmet medical needs. I can already clearly see Perspective Therapeutics’ strong team and scientific foundation, energizing the Company’s mission and driving forces towards changing the landscape of cancer treatments through precision targeted medicine,” noted Heidi Henson, incoming member of the Board.

Lori Woods, Chair of the Board commented, “On behalf of Perspective Therapeutics, we wish Heidi a warm welcome and look forward to her active presence on the board and leadership as Audit Committee Chair.”

Thijs Spoor, Perspective Therapeutics’ CEO added, “We are truly delighted to have Heidi join the board of directors at this important juncture in the Company’s evolutionary lifecycle. Her deep leadership experience, while at the helm of life sciences companies, complements the synergies that are coming following on from the combination of Isoray and Viewpoint Molecular Targeting. As a commercial stage brachytherapy company, also focused on early stage development of precision targeted therapies; we are committed to transforming the lives of cancer patients by advancing the field of theranostic and alpha-particle radiotherapies. In this spirit, we are certain that Heidi’s guidance will help us to move further along in our objectives.”

As incoming Chair of the Audit Committee, Ms. Henson is a financial professional with over 25 years of executive leadership roles in the life sciences. In past executive leadership roles, Ms. Henson has served as the Chief Financial Officer of Pardes Biosciences, Imbria Pharmaceuticals, Respivant Sciences, Kura Oncology, Wellspring Biosciences, and Araxes Pharma. Ms. Henson is also currently serving on the board of directors of PepGen and Lista Therapeutics.

Ms. Woods also commented on Mr. McCormick’s departure, “As a longstanding member of the board, we hold Michael in the highest esteem. He has been both a wonderful colleague and advisor to the organization these last 8 years and we are sad to see him depart. On behalf of the whole board, we would like to thank him for his leadership and truly wish him all the best in his endeavors.”

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com .

Investor Relations Contact:
LifeSci Advisors
Chuck Padala
E: chuck@lifesciadvisors.com

Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies

New corporate tagline and website introduced

New ticker symbol to be NYSE American: CATX

RICHLAND, Wash. and CORALVILLE, Iowa, Feb. 07, 2023 — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy and its newly merged partner Viewpoint Molecular Targeting, Inc., today announced that they are now doing business as Perspective Therapeutics, Inc., along with a new brand identity effective immediately. Isoray, Inc. will change its name to Perspective Therapeutics, Inc. by filing an amendment to its Certificate of Incorporation as soon as possible.

Post-merger rebranding highlights include:

• New tagline: “Treating cancers from the inside out“
• New corporate website https://www.perspectivetherapeutics.com
• New NYSE American stock ticker symbol to be CATX, effective February 21, 2023

“We believe that Perspective Therapeutics truly reflects our potential to transform the field of precision oncology medicine and the outcome of early-stage cancers through the advancement of radiopharmaceuticals,” said Perspective Therapeutics, Inc. CEO Thijs Spoor. “On behalf of Perspective Therapeutics board of directors, employees and myself we look forward to bringing the Company’s focus, as well as our commercial and strategic pipeline development objectives to life.”

The Company currently trades on the NYSE American as Isoray, Inc. under ticker symbol ISR which will change to Perspective Therapeutics, Inc. with the ticker symbol of CATX on February 21, 2023.

Oppenheimer & Co. acted as Isoray’s financial advisor for the merger transaction and Gallagher & Kennedy, P.A. served as Isoray’s legal counsel. Sichenzia Ross Ference, LLP acted as Viewpoint’s legal counsel.

About Perspective Therapeutics, Inc.
Isoray, Inc. (soon to operate as Perspective Therapeutics, Inc.) is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement
Statements in this news release about Isoray’s future expectations, including those regarding the name and ticker symbol change and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing Isoray of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as completion and timing of filing an amendment to its Certificate of Incorporation in Delaware and amendment of any agreements necessary to make effective the name change and approval of the change in ticker symbol by the NYSE American Exchange. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
Isoray Investor Relations: Mark Levin (501) 255-1910
Viewpoint Investor Relations: Chuck Padala (941) 741-7792
Media and Public Relations: Sharon Schultz (302) 539-3747

CORALVILLE, Iowa –
Viewpoint Molecular Targeting^®, Inc., a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents, today announced the first dosing of two neuroendocrine tumor patients with therapeutic intent. VMT-α-NET, which is being developed for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2) expressing neuroendocrine tumors, was administered to the patients in early December. The dosed patients were diagnosed with confirmed-advanced somatostatin expressing neuroendocrine tumors (NETs).

The administration of VMT-α-NET was under the supervision of the patients’ doctor, Dr. Ishida Sen MBBS, Director and Head of Nuclear Medicine at Fortis Hospital, New Delhi, in partnership with BJ Madan, a diagnostic & therapeutic radiopharmaceutical company in New Delhi. No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and in good condition.

“Preclinical and clinical data associated with this new radiopharmaceutical demonstrates significant potential to help our NET patients,” noted Dr. Sen. “We are pleased that the patients are doing well, and we have appreciated the professionalism and scientific strength of the Viewpoint team.”

Under compassionate use circumstances, VMT-α-NET may be made available to qualified doctors in some countries. In this circumstance, Viewpoint supplied drug precursors and isotopes for the local production of its proprietary radiotherapeutic, VMT-α-NET.

“We are highly committed to the rapid development of alpha-particle radionuclide therapy for cancer,” said Viewpoint CEO Thijs Spoor. “We are pleased to support Dr Sen’s team in making this product available for her patients.”

The progress of these patients will be followed by Dr. Sen and her team over the coming months. The safety and effectiveness of the treatments will be evaluated by Dr. Sen’s team with laboratory testing, observation of NET-associated symptoms, and repeat medical imaging.

In the U.S., VMT-α-NET will imminently enter a Phase 1 imaging and therapy study, to be conducted at various hospitals and clinics. VMT-α-NET, is categorized as an investigational new drug by the U.S. Food and Drug Association and the administration of VMT-α-NET for compassionate use is completely independent from and not within the scope of the Company’s Phase 1 trial.

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. For more information about Viewpoint and its emerging treatments, please visit the Company’s website www.viewpointmt.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005190/en/

Investors

Chuck Padala

LifeSci Advisors, LLC

917-741-7792

chuck@lifesciadvisors.com

SBIR Phase II Grants bring the cumulative grant total to approximately $17 million from the National Institutes of Health and National Cancer Institute

CORALVILLE, IA / October 11, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the award of two additional Small Business Innovation Research (SBIR) phase II grants totaling $4 million. The first award of $2 million is intended to assess image-guided dosimetry-based alpha particle therapy for neuroblastoma. The second award of $2 million was awarded for the purpose of combining receptor-targeted alpha particle therapy and immunotherapy to achieve complete responses in metastatic melanoma. These recently awarded grants bring the total amount of SBIR awards of approximately $17 million through October 2022 from the National Institutes of Health (NIH) and National Cancer Institute (NCI) to our principal collaborators at the University of Iowa, including Michael K. Schultz, PhD, our co-founder and Chief Scientific Officer, and Frances L. Johnson, MD, our co-founder and Chief Operating Officer.

“We are grateful that our science has been recognized since the Company’s inception with such significant support from the NIH and NCI to support our targeted alpha therapy development activities,” said Thijs Spoor, CEO of Viewpoint Molecular Targeting.

Dr. Schultz commented, “as our researchers continue to expand the potential applications of targeted alpha therapies generally, and the compelling science behind Pb-212 specifically, we continue to be excited by the transformational nature we think our emerging discoveries will have on the lives of cancer patients.”

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website www.viewpointmt.com.

Viewpoint previously announced on September 29, 2022 that it has entered into a definitive agreement to merge with Isoray, Inc. (NYSE AMERICAN:ISR (“Isoray”)), a medical technology company and innovator in seed brachytherapy. Additional details regarding the contemplated merger along with the merger agreement can be found in Isoray’s current report on Form 8-K which was filed with the Securities and Exchange Commission on September 28, 2022. The consummation of the merger is subject to approval by the shareholders of both Isoray and Viewpoint along with other customary closing conditions.

Forward-Looking Statements

This press release contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s expectations or forecasts regarding future events. These statements can be identified by the fact they do not relate strictly to historical or current facts. They may use words such as “believe,” “potential,” “estimate,” “expect,” “will,” and other terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, forward-looking statements include statements relating to intended future actions; the Company’s expectations about its addressable markets and market share; the consummation of the merger with Isoray and the realization of the anticipated benefits of the combination; the functionality and capabilities of the Company’s therapies; the potential size of the commercial market for the Company’s treatment programs; and the Company’s expectations beliefs, intentions or strategies regarding the future. Any or all of the Company’s forward-looking statements here and elsewhere may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements and from expected or historical results. Many such factors will be important in determining the Company’s actual future results. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to correct or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law. These forward-looking statements (except as may be otherwise noted) speak only as of the date of this press release. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them.

Contacts

Investor / Media / Public Relations: Thijs Spoor (319) 665-2150

SOURCE: Viewpoint Molecular Targeting, Inc.

View source version on accesswire.com:
https://www.accesswire.com/719847/Viewpoint-Molecular-Targeting-Announces-Two-New-Grant-Awards-of-2-Million-Each

Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs

CORALVILLE, IA / October 4, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of Markus Puhlmann, MD, MBA as Chief Medical Officer (CMO).

“Markus joins Viewpoint with an impressive track record of building and leading successful oncology programs,” said Thijs Spoor, CEO of Viewpoint Molecular Targeting. “His broad, global experience across many tumor types at all stages of clinical development make him the ideal candidate to join Viewpoint as CMO. I am thrilled to have Markus on our management team and look forward to working together.”

Dr Puhlmann has 20 years of experience in oncology drug development in solid and liquid tumor indications. Before joining Viewpoint, he was the CD30 Franchise Head of Global Clinical Development, Seagen. Prior to his time at Seagen, Dr. Puhlmann’s work as Section Head at Merck & Co led to many successful regulatory filings for pembrolizumab in various indications for urothelial carcinoma, RCC and cervical cancer. Earlier in his career, he held various positions with increasing responsibilities in clinical development and medical affairs at Schering Plough, Bayer and Amgen. Dr. Puhlmann began his career as an academic physician in Germany, the UK and in the US at the National Cancer Institute (NCI).

Dr. Puhlmann commented, “The opportunity to lead the development of Viewpoint’s pipeline programs is extremely exciting for me as a cancer drug developer. I think the application of targeted alpha-particle therapy will have a profound impact on the treatment of oncology patients.”

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT- -NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website www.viewpointmt.com.

Viewpoint previously announced on September 29, 2022 that it has entered into a definitive agreement to merge with Isoray, Inc. or Isoray (NYSE AMERICAN:ISR (“Isoray”)), a medical technology company and innovator in seed brachytherapy. Additional details regarding the contemplated merger along with the merger agreement can be found in Isoray’s current report on Form 8-K which was filed with the Securities and Exchange Commission on September 28, 2022. The consummation of the merger is subject to approval by the shareholders of both Isoray and Viewpoint along with other customary closing conditions.

Forward-Looking Statements

This press release contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s expectations or forecasts regarding future events. These statements can be identified by the fact they do not relate strictly to historical or current facts. They may use words such as “believe,” “potential,” “estimate,” “expect,” “will,” and other terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, forward-looking statements include statements relating to intended future actions; the Company’s expectations about its addressable markets and market share; the consummation of the merger with Isoray and the realization of the anticipated benefits of the combination; the functionality and capabilities of the Company’s therapies; the potential size of the commercial market for the Company’s treatment programs; and the Company’s expectations beliefs, intentions or strategies regarding the future. Any or all of the Company’s forward-looking statements here and elsewhere may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements and from expected or historical results. Many such factors will be important in determining the Company’s actual future results. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to correct or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law. These forward-looking statements (except as may be otherwise noted) speak only as of the date of this press release. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them.

Contacts
Investor / Media / Public Relations: Thijs Spoor (319) 665-2150

SOURCE: Viewpoint Molecular Targeting, Inc.

View source version on accesswire.com:
https://www.accesswire.com/718693/Viewpoint-Molecular-Targeting-Announces-Appointment-of-Markus-Puhlmann-MD-MBA-as-Chief-Medical-Officer

CORALVILLE, IA / October 3, 2022 / Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of [²¹²Pb]VMT-α-NET for treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs) (including GEP-NETs or bronchial NETs and pheochromocytomas and paragangliomas).

“Although several exciting new medicines have emerged in the past decade for patients with neuroendocrine tumors, there remains an unmet need for certain patient segments, where survival rates remain low” said Dr Frances Johnson, M.D., COO and co-founder of Viewpoint. Added Michael Schultz, Ph.D., CSO and co-founder of Viewpoint, “we applied for fast track designation based on the compelling results seen in head-to-head animal studies and are appreciative of the FDA being able to review the data expeditiously.” The Company expects the results of those studies to be presented publicly at the upcoming European Association of Nuclear Medicine (EANM) conference to be held October 15-19, 2022 in Barcelona, Spain.

“We are thrilled to receive FDA Fast Track Designation for our leading program,” said Thijs Spoor, CEO of Viewpoint. “This designation will allow us to actively explore the fastest ways to bring our personalized alpha-particle theranostics to patients.”

The FDA Fast Track Designation is one of several approaches utilized by the FDA to expedite development and review of potential medicines for serious conditions and that fulfill unmet medical needs. A potential new medicine may fill an unmet medical need by being the first therapy to address a specific serious condition, offer clinically significant advantages over available therapies, act via a different mechanism of action than available therapies, or have a benefit in patients who are unresponsive to or intolerant of available therapies. Programs that receive Fast Track Designation are entitled to more frequent interactions with the FDA on drug development plan, as well as eligibility for accelerated approval, priority review, and rolling review.

About Neuroendocrine Tumors (NET)

Neuroendocrine tumors form in cells that interact with the nervous system or in glands that produce hormones. They can originate in various parts of the body, most often in the gut or the lungs and can be benign or malignant. Neuroendocrine tumors are typically classified as pancreatic neuroendocrine tumors or non-pancreatic neuroendocrine tumors. According to cancer.net, it is estimated that more than 12,000 people in the United States are diagnosed with a NET each year. Importantly, neuroendocrine tumors are associated with a relatively long duration of survival compared to other tumors and as a result, there are approximately 175,000 people living with this diagnosis.

About Viewpoint Molecular Targeting

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT- -NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. For more information, please visit the Company’s website www.viewpointmt.com.

Viewpoint previously announced on September 29, 2022 that it has entered into a definitive agreement to merge with Isoray, Inc (NYSE AMERICAN:ISR), a medical technology company and innovator in seed brachytherapy. Additional details regarding the contemplated merger along with the merger agreement can be found in Isoray Inc.’s current report on Form 8-K which was filed with the Securities and Exchange Commission on September 28, 2022. The consummation of the merger is subject to approval by the shareholders of both Isoray and Viewpoint along with other customary closing conditions.

Forward-Looking Statements

This press release contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s expectations or forecasts regarding future events. These statements can be identified by the fact they do not relate strictly to historical or current facts. They may use words such as “believe,” “potential,” “estimate,” “expect,” “will,” and other terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, forward-looking statements include statements relating to intended future actions; the Company’s expectations about its addressable markets and market share; the consummation of the merger with Isoray and the realization of the anticipated benefits of the combination; the functionality and capabilities of the Company’s therapies; the potential size of the commercial market for the Company’s treatment programs; and the Company’s expectations beliefs, intentions or strategies regarding the future. Any or all of the Company’s forward-looking statements here and elsewhere may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements and from expected or historical results. Many such factors will be important in determining the Company’s actual future results. Consequently, no forward-looking statement can be guaranteed. The Company undertakes no obligation to correct or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law. These forward-looking statements (except as may be otherwise noted) speak only as of the date of this press release. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them.

Contacts

Investor / Media / Public Relations: Thijs Spoor (319) 665-2150

SOURCE: Viewpoint Molecular Targeting, Inc.

View source version on accesswire.com:
https://www.accesswire.com/718474/Viewpoint-Molecular-Targeting-Announces-VMT-NET-Granted-US-FDA-Fast-Track-Destination-for-the-Treatment-of-Neuroendocrine-Tumors